Alexandre Reuben, Ph.D.
Alexandre Reuben, Ph.D.
Assistant Professor, MD Anderson Cancer Center
Verified email at
Cited by
Cited by
Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
V Gopalakrishnan, CN Spencer, L Nezi, A Reuben, MC Andrews, ...
Science 359 (6371), 97-103, 2018
B cells and tertiary lymphoid structures promote immunotherapy response
BA Helmink, SM Reddy, J Gao, S Zhang, R Basar, R Thakur, K Yizhak, ...
Nature 577 (7791), 549-555, 2020
Defining T cell states associated with response to checkpoint immunotherapy in melanoma
M Sade-Feldman, K Yizhak, SL Bjorgaard, JP Ray, CG de Boer, ...
Cell 175 (4), 998-1013. e20, 2018
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine
LT Geller, M Barzily-Rokni, T Danino, OH Jonas, N Shental, D Nejman, ...
Science 357 (6356), 1156-1160, 2017
The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy
V Gopalakrishnan, BA Helmink, CN Spencer, A Reuben, JA Wargo
Cancer cell 33 (4), 570-580, 2018
Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade
PL Chen, W Roh, A Reuben, ZA Cooper, CN Spencer, PA Prieto, JP Miller, ...
Cancer discovery 6 (8), 827-837, 2016
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
W Roh, PL Chen, A Reuben, CN Spencer, PA Prieto, JP Miller, ...
Science translational medicine 9 (379), eaah3560, 2017
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
RN Amaria, SM Reddy, HA Tawbi, MA Davies, MI Ross, IC Glitza, ...
Nature medicine 24 (11), 1649-1654, 2018
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
T Cascone, WN William Jr, A Weissferdt, CH Leung, HY Lin, A Pataer, ...
Nature medicine 27 (3), 504-514, 2021
Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
SC Wei, NAAS Anang, R Sharma, MC Andrews, A Reuben, JH Levine, ...
Proceedings of the National Academy of Sciences 116 (45), 22699-22709, 2019
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised …
RN Amaria, PA Prieto, MT Tetzlaff, A Reuben, MC Andrews, MI Ross, ...
The Lancet Oncology 19 (2), 181-193, 2018
Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases
GM Fischer, A Jalali, DA Kircher, WC Lee, JL McQuade, LE Haydu, ...
Cancer discovery 9 (5), 628-645, 2019
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
MC Andrews, CPM Duong, V Gopalakrishnan, V Iebba, WS Chen, ...
Nature medicine 27 (8), 1432-1441, 2021
Identification of bacteria-derived HLA-bound peptides in melanoma
S Kalaora, A Nagler, D Nejman, M Alon, C Barbolin, E Barnea, ...
Nature 592 (7852), 138-143, 2021
Defining T cell states associated with response to checkpoint immunotherapy in melanoma
M Sade-Feldman, K Yizhak, SL Bjorgaard, JP Ray, CG de Boer, ...
Cell 176 (1), 404, 2019
TCR repertoire intratumor heterogeneity in localized lung adenocarcinomas: an association with predicted neoantigen heterogeneity and postsurgical recurrence
A Reuben, R Gittelman, J Gao, J Zhang, EC Yusko, CJ Wu, R Emerson, ...
Cancer discovery 7 (10), 1088-1097, 2017
Immune effects of chemotherapy, radiation, and targeted therapy and opportunities for combination with immunotherapy
JA Wargo, A Reuben, ZA Cooper, KS Oh, RJ Sullivan
Seminars in oncology 42 (4), 601-616, 2015
Comprehensive T cell repertoire characterization of non-small cell lung cancer
A Reuben, J Zhang, SH Chiou, RM Gittelman, J Li, WC Lee, J Fujimoto, ...
Nature communications 11 (1), 603, 2020
Immuno-genomic landscape of osteosarcoma
CC Wu, HC Beird, J Andrew Livingston, S Advani, A Mitra, S Cao, ...
Nature communications 11 (1), 1008, 2020
Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma
A Reuben, CN Spencer, PA Prieto, V Gopalakrishnan, SM Reddy, ...
NPJ genomic medicine 2 (1), 10, 2017
The system can't perform the operation now. Try again later.
Articles 1–20